AIA
LKFT

Avalon Investment & Advisory’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Avalon Investment & Advisory’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,901
Closed -$554K – 341
2020
Q3 		$554K Buy
+3,901
New +$650K 0.01% 260

Other funds holding LKFT

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Avalon Investment & Advisory's LKFT Position: Q4 2020 in Review

Avalon Investment & Advisory sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2020, closing a stake of 3,901 shares — an estimated $554K sold.

Avalon Investment & Advisory first reported a position in LKFT in Q3 2020 and held it in 1 quarter. The position peaked at $554K in Q3 2020. 116 funds tracked by Wall St. Rank hold LKFT as of Q4 2020.

  • Avalon Investment & Advisory reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2020 after selling out during the quarter.
  • Avalon Investment & Advisory sold 3,901 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2020, an estimated $554K.
  • Avalon Investment & Advisory first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2020 and held it in 1 quarter.
  • Avalon Investment & Advisory's Lakefront Biotherapeutics American Depositary Shares position peaked at $554K in Q3 2020.
  • 116 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2020.

Based on Avalon Investment & Advisory's 13F filing for Q4 2020, filed 8 Feb 2021.